Hemophilia: Clinical Practice, January 11, 1994

Hemophilia: Clinical Practice, January 11, 1994

<!-- translated-chunk:20/63 -->

This disease is a hereditary coagulation disorder. Incidence: According to a survey by the U.S. National Institutes of Health, there are approximately 26 cases per 100,000 people; the disease generally includes hemophilia A, hemophilia B, and vascular hemophilia. Due to early diagnosis, home treatment, and collaboration among various clinical departments, the survival period of hemophilia has significantly increased, mortality has greatly decreased, and average life expectancy is now close to that of the general population. The pathogenesis of this disease is related to the human immunodeficiency virus, which can cause AIDS. Japanese scholars have reported that among 4,000 patients with this disease, 34 were also infected with AIDS, more than 20 times higher than in the general population. In addition, a large number of hemophilia patients suffer from various types of hepatitis. Polish scholars found that among 960 hemophilia patients, infections with various hepatitis viruses were very common; these patients were treated with interferon, vidarabine, and levamisole, achieving an effective rate of 80%. These drugs are all effective against the immunodeficiency virus. Hemophilia patients often have osteoarthritis and oral inflammation as well. Treatment: Early blood transfusion, later plasma therapy; since 1964, cryoprecipitate has been used to treat this disease. In 1985, new coagulation factor preparations were introduced, and in recent years, liver transplantation has also been adopted.